A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2016
At a glance
- Drugs Cannabidiol (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors GW Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 19 May 2015 Results presented at the Digestive Disease Week 2015.
- 14 Oct 2014 Primary endpoint of 'percentage of participants achieving remission quantified as a MAYO score of 2 or less (with no subscore1)' has not been met, according to a GW Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History